Format

Send to

Choose Destination
Cell Biol Toxicol. 2019 Feb 15. doi: 10.1007/s10565-019-09465-9. [Epub ahead of print]

Proteomic and genomic profiling of pancreatic cancer.

Author information

1
Department of Surgery, Clinical Sciences Lund, Skåne University Hospital, Lund University, SE-221 85, Lund, Sweden. daniel.ansari@med.lu.se.
2
Department of Surgery, Clinical Sciences Lund, Skåne University Hospital, Lund University, SE-221 85, Lund, Sweden.
3
School of Ophthalmology and Optometry, Eye Hospital, Wenzhou Medical University, Wenzhou, China.
4
Department of Gastroenterology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China.

Abstract

Pancreatic cancer remains the most fatal human tumor type. The aggressive tumor biology coupled with the lack of early detection strategies and effective treatment are major reasons for the poor survival rate. Collaborative research efforts have been devoted to understand pancreatic cancer at the molecular level. Large-scale genomic studies have generated important insights into the genetic drivers of pancreatic cancer. In the post-genomic era, protein sequencing of tumor tissue, cell lines, pancreatic juice, and blood from patients with pancreatic cancer has provided a fundament for the development of new diagnostic and prognostic biomarkers. The integration of mass spectrometry and genomic sequencing strategies may help characterize protein identities and post-translational modifications that relate to a specific mutation. Consequently, proteomic and genomic techniques have become a compulsory requirement in modern medicine and health care. These types of proteogenomic studies may usher in a new era of precision diagnostics and treatment in patients with pancreatic cancer.

KEYWORDS:

Biomarkers; Genomics; Pancreatic cancer; Proteogenomics; Proteomics

PMID:
30771135
DOI:
10.1007/s10565-019-09465-9

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center